Patients
Clostridium botulinum toxin type A, diabetes, neurological diseases
FACIAL SEBORRHEIC DERMATITIS, SEBORRHEIC DERMATITIS, THYROID DISEASES
This research was conducted in the form of a prospective, single‐arm clinical trial. At the beginning of the study, necessary permits were obtained to collect information from the patients. The research sample in this study consists of all patients referred to the dermatology clinic, from March 2019 to March 2021, who received botulinum toxin injection for removal of facial wrinkles and have Scalp or facial seborrheic dermatitis at the same time. The method of injection involved the administration of 150 units of Clostridium botulinum toxin type A (MASPORT®) into specific facial muscles, including the frontalis (forehead), procerus (between the eyebrows), orbicularis oculi (around the eyes) and corrugator muscles (between the eyebrows). Sampling of the study was done by convenience method and by examining all the available samples regarding to inclusion and exclusion criteria.The exclusion criteria:
The patients undergoing other treatment to control the symptoms of seborrheic dermatitis.The patients have lost to follow up after one month of injection through a repeat visit.During the conduct of this study, after obtaining verbal permission and explaining the objectives of the study to the patients, information such as demographic data (age and gender), history of diabetes, neurological diseases, thyroid diseases, drug use and history and frequency of Botox injections, was recorded.